Clin2
NCT06210295Possibly a fitNot yet recruiting

Anemia treatment for lupus patients

Refractory Anemia in Systemic Lupus Erythematosis

Part of Blood & lymphatic, Immune system & allergy clinical trials.

This trial is looking at why people with lupus develop anemia that doesn't improve with standard treatments. It may help find better ways to manage this condition.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
67 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older
  • You have been diagnosed with lupus (systemic lupus erythematosus)
  • You have anemia (low red blood cells)
  • You are not pregnant
  • You do not have mixed connective tissue disease

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07725497Recruiting· Phase 2
Luspatercept for anemia from chronic kidney disease

This trial tests a drug called luspatercept to see if it can raise hemoglobin levels in people with anemia caused by chronic kidney disease. It's for those whose current treatments aren't working well or who cannot use them.

Basking Ridge, New Jersey
NCT07175285Recruiting
Study for lupus patients not helped by steroids and 2 immunosuppressants

This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.

Mesa, Arizona
NCT07663864Recruiting· Phase 1/Phase 2
Luspatercept for anemia after AML treatment

This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.

Guangzhou, Guangdong
NCT06920433Recruiting· Early Phase 1
Targeted cell therapy for tough lupus with kidney involvement

This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.

Hangzhou, Zhejiang
NCT07323173Recruiting· Phase 1
Safety study of LBL-047 in healthy adults and lupus patients

This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.

Bengbu, Anhui
NCT07314567Not yet recruiting
Study of ACE1831 for active lupus in adults

This trial tests a new treatment called ACE1831 for people with moderate to severe lupus that has not improved with standard treatments like steroids or other medications. The goal is to see if it can help control lupus activity.

Wuhan, Hubei

Hear when a new Refractory Anemia in Systemic Lupus Erythematosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.